-

04:14:37 AM

BNTC Stock News

BNTC - Benitec Biopharma Inc

01/23/23 9:48 AM

Nasdaq : BNTC

clinical trial

Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program

Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform,

RHEA-AI

neutral

11/10/22 8:00 AM

Nasdaq : BNTC

earnings

Benitec Biopharma Releases First Quarter 2023 Financial Results and Provides Operational Update

Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform,

RHEA-AI

neutral

09/16/22 8:42 AM

Nasdaq : BNTC

offering

Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering

Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform,

RHEA-AI

neutral

09/12/22 10:06 PM

Nasdaq : BNTC

offering

Benitec Biopharma Inc. Announces Pricing of $18 Million Underwritten Public Offering

Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform,

RHEA-AI

neutral

09/02/22 8:00 AM

Nasdaq : BNTC

earnings

Benitec Biopharma Releases Full Year 2022 Financial Results and Provides Operational Update

Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform,

RHEA-AI

neutral

05/16/22 8:15 AM

Nasdaq : BNTC

earnings

Benitec Biopharma Releases Q3 2022 Financial Results

Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform,

RHEA-AI

neutral

02/14/22 8:00 AM

Nasdaq : BNTC

earnings

Benitec Biopharma Discloses Q2 2022 Financial Results

Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today

RHEA-AI

neutral

11/15/21 8:00 AM

Nasdaq : BNTC

earnings

Benitec Biopharma Discloses Q1 2022 Financial Results

Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today

RHEA-AI

neutral

09/20/21 8:00 AM

Nasdaq : BNTC

earnings

Benitec Biopharma Provides Operational Update and Releases its 2021 Fiscal Year-End Financial Results

Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today

RHEA-AI

neutral

09/13/21 3:58 PM

Nasdaq : BNTC

conferences

Benitec Biopharma to present at H.C. Wainwright's 23rd Annual Global Investment Conference

Benitec Biopharma, Inc. (NASDAQ: BNTC), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that Jerel A.

RHEA-AI

neutral